Assignee
THERAVANCE BIOPHARMA R&D IP LLC
US·172 granted patents·25 pending applications·717 citations·filing 2014–2024
Top patents by PatentIndex Score
197 records- 0198US11247969B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Feb 15, 2022·6 cites·10 claims
- 0298US10526330B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 7, 2020·15 cites·13 claims
- 0398US10208040B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 19, 2019·24 cites·31 claims
- 0498US10196393B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 5, 2019·24 cites·12 claims
- 0598US10100049B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Oct 16, 2018·28 cites·17 claims
- 0697US11420965B2Pyrimidine compound as JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Aug 23, 2022·3 cites·18 claims
- 0797US11390603B2Crystalline forms of a biphenyl compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jul 19, 2022·5 cites·6 claims
- 0897US10946006B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Mar 16, 2021·4 cites·25 claims
- 0997US10774080B2Pyrimidine compound as JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Sep 15, 2020·5 cites·22 claims
- 1097US10722504B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jul 28, 2020·5 cites·18 claims
- 1197US10548886B2Methods of treatment using a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 4, 2020·17 cites·18 claims
- 1297US10550118B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 4, 2020·13 cites·10 claims
- 1397US10519153B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 31, 2019·16 cites·22 claims
- 1497US10406148B2Methods of treatment using a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Sep 10, 2019·24 cites·15 claims
- 1597US10392386B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 27, 2019·19 cites·10 claims
- 1697US10206913B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 19, 2019·11 cites·2 claims
- 1797US10183942B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 22, 2019·23 cites·6 claims
- 1897US10034870B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jul 31, 2018·12 cites·10 claims
- 1997US9725470B2Substituted naphthyridines as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Aug 8, 2017·27 cites·19 claims
- 2096US11780852B2Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrileTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Oct 10, 2023·3 cites·55 claims
- 2196US11634419B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 25, 2023·6 cites·20 claims
- 2296US10988470B2Pyrimidine compound as JAK kinase inhibitorTHERAVANCE BIOPHARMA R & D IP LLC·Filed 2020·Granted Apr 27, 2021·3 cites·19 claims
- 2396US10570092B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 25, 2020·8 cites·5 claims
- 2496US10562894B2Pyrimidine compound as JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 18, 2020·7 cites·19 claims
- 2596US10493077B2Fused imidazo-piperidine JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 3, 2019·14 cites·19 claims
- 2696US10343995B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jul 9, 2019·9 cites·23 claims
- 2796US10308646B2Pyrimidine compound as JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jun 4, 2019·11 cites·32 claims
- 2895US11008289B2Crystalline freebase forms of a biphenyl compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted May 18, 2021·5 cites·9 claims
- 2995US10947229B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·10 cites·15 claims
- 3095US10946007B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Mar 16, 2021·2 cites·4 claims
- 3195US10836763B25 to 7 membered heterocyclic amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 17, 2020·12 cites·20 claims
- 3295US10441579B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Oct 15, 2019·7 cites·9 claims
- 3395US10251874B2Crystalline forms of a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Apr 9, 2019·23 cites·23 claims
- 3495US10226454B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Mar 12, 2019·8 cites·18 claims
- 3595US10106503B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Oct 23, 2018·9 cites·25 claims
- 3695US10028960B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jul 24, 2018·18 cites·13 claims
- 3795US9926272B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Mar 27, 2018·9 cites·7 claims
- 3895US9873685B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 23, 2018·10 cites·7 claims
- 3994US11702415B2Crystalline hydrate of a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Jul 18, 2023·6 cites·22 claims
- 4094US11453668B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Sep 27, 2022·2 cites·20 claims
- 4194US11155549B2Ester and carbonate pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Oct 26, 2021·5 cites·26 claims
- 4294US10913740B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 9, 2021·5 cites·18 claims
- 4394US10759813B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Sep 1, 2020·3 cites·18 claims
- 4494US10576073B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 3, 2020·6 cites·11 claims
- 4594US10189823B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 29, 2019·9 cites·3 claims
- 4694US9845332B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Dec 19, 2017·7 cites·1 claims
- 4794US9656993B2Crystalline forms of a biphenyl compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2015·Granted May 23, 2017·10 cites·7 claims
- 4893US11299492B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 12, 2022·2 cites·13 claims
- 4993US11254669B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 22, 2022·3 cites·17 claims
- 5093US11230536B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 25, 2022·2 cites·20 claims
Showing the top 50 of 197 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when THERAVANCE BIOPHARMA R&D IP LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →